Suppr超能文献

利用大鼠肝基因表达的因果推理来鉴定药物性肝损伤的分子途径。

Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury.

机构信息

* Selventa Inc., Cambridge, Massachusetts 02140;

出版信息

Toxicol Sci. 2014 Jan;137(1):234-48. doi: 10.1093/toxsci/kft232. Epub 2013 Oct 17.

Abstract

Drug-induced liver injury (DILI) represents a leading cause of acute liver failure. Although DILI can be discovered in preclinical animal toxicology studies and/or early clinical trials, some human DILI reactions, termed idiosyncratic DILI (IDILI), are less predictable, occur in a small number of individuals, and do not follow a clear dose-response relationship. The emergence of IDILI poses a critical health challenge for patients and a financial challenge for the pharmaceutical industry. Understanding the cellular and molecular mechanisms underlying IDILI is key to the development of models that can assess potential IDILI risk. This study used Reverse Causal Reasoning (RCR), a method to assess activation of molecular signaling pathways, on gene expression data from rats treated with IDILI or pharmacologic/chemical comparators (NON-DILI) at the maximum tolerated dose to identify mechanistic pathways underlying IDILI. Detailed molecular networks involved in mitochondrial injury, inflammation, and endoplasmic reticulum (ER) stress were found in response to IDILI drugs but not negative controls (NON-DILI). In vitro assays assessing mitochondrial or ER function confirmed the effect of IDILI compounds on these systems. Together our work suggests that using gene expression data can aid in understanding mechanisms underlying IDILI and can guide in vitro screening for IDILI. Specifically, RCR should be considered for compounds that do not show evidence of DILI in preclinical animal studies positive for mitochondrial dysfunction and ER stress assays, especially when the therapeutic index toward projected human maximum drug plasma concentration is low.

摘要

药物性肝损伤(DILI)是急性肝衰竭的主要原因之一。尽管在临床前动物毒理学研究和/或早期临床试验中可以发现 DILI,但某些人类 DILI 反应,称为特异质 DILI(IDILI),则不太可预测,仅发生在少数个体中,且不符合明确的剂量反应关系。IDILI 的出现给患者带来了严峻的健康挑战,也给制药行业带来了财务挑战。了解 IDILI 背后的细胞和分子机制是开发能够评估潜在 IDILI 风险的模型的关键。本研究使用反向因果推理(RCR)方法,对在最大耐受剂量下接受 IDILI 药物或药理学/化学对照剂(NON-DILI)治疗的大鼠的基因表达数据进行评估,以识别 IDILI 的分子信号通路激活,从而确定 IDILI 的潜在机制。在 IDILI 药物治疗后会出现与线粒体损伤、炎症和内质网(ER)应激相关的详细分子网络,但在阴性对照(NON-DILI)中则没有出现。评估线粒体或 ER 功能的体外检测证实了 IDILI 化合物对这些系统的影响。综上所述,我们的工作表明,使用基因表达数据可以帮助了解 IDILI 的潜在机制,并可以指导 IDILI 的体外筛选。具体而言,当针对预期的人类最大药物血浆浓度的治疗指数较低时,对于在临床前动物研究中显示出对线粒体功能障碍和 ER 应激检测呈阳性、但没有证据表明存在 DILI 的化合物,应考虑使用 RCR 方法,尤其是当针对预期的人类最大药物血浆浓度的治疗指数较低时。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验